Deciphera Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Deciphera Pharmaceuticals today announced that CEO Steve Hoerter will present at the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021, at 9:10 AM ET. A live webcast will be available on the company's website, with a replay archived for 90 days post-event.

Deciphera focuses on developing innovative cancer treatments, leveraging its proprietary switch-control kinase inhibitor platform. Its FDA-approved QINLOCK is specifically for fourth-line gastrointestinal stromal tumor (GIST) treatment, also approved in Canada and Australia.

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will present at the 39^th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 9:10 AM ET.

A live webcast of the event will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investors.deciphera.com/news-events/events-presentations. A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.

About Deciphera Pharmaceuticals

Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK is Deciphera’s FDA-approved switch-control kinase inhibitor for the treatment of fourth-line gastrointestinal stromal tumor (GIST). QINLOCK is also approved for fourth-line GIST in Canada and Australia. For more information, visit www.deciphera.com and follow us on LinkedIn and Twitter (@Deciphera).

View source version on businesswire.com: https://www.businesswire.com/news/home/20210105005523/en/

FAQ

When will Deciphera Pharmaceuticals present at the J.P. Morgan Healthcare Conference?

Deciphera Pharmaceuticals will present on January 11, 2021, at 9:10 AM ET.

How can I watch the Deciphera Pharmaceuticals presentation?

The presentation can be watched via a live webcast on Deciphera's 'Events and Presentations' page on their website.

What is QINLOCK and its approval status?

QINLOCK is Deciphera's FDA-approved switch-control kinase inhibitor for fourth-line gastrointestinal stromal tumor (GIST), also approved in Canada and Australia.

What is the purpose of Deciphera Pharmaceuticals?

Deciphera Pharmaceuticals aims to discover, develop, and commercialize new medicines to improve the lives of cancer patients.

Where can I find more information about Deciphera Pharmaceuticals?

More information can be found on Deciphera's official website at www.deciphera.com.